MRK logo

Merck KGaA Stock Price

XTRA:MRK Community·€48.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 70 Fair Values set on narratives written by author

MRK Share Price Performance

€110.60
-27.70 (-20.03%)
€143.47
Fair Value
€110.60
-27.70 (-20.03%)
22.9% undervalued intrinsic discount
€143.47
Fair Value
Price €110.60
AnalystConsensusTarget €143.47
AnalystLowTarget €100.00
AnalystHighTarget €191.00

MRK Community Narratives

AnalystConsensusTarget·
Fair Value €143.47 22.9% undervalued intrinsic discount

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

0users have liked this narrative
0users have commented on this narrative
48users have followed this narrative
AnalystLowTarget·
Fair Value €105.5 4.8% overvalued intrinsic discount

Legacy Pharmaceutical And Chemical Businesses Will Decline As Regulations Tighten

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystHighTarget·
Fair Value €191 42.1% undervalued intrinsic discount

Aging Populations And Digitalization Will Unlock Life Sciences Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€105.5
4.8% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
1.81% p.a.
Profit Margin
13.85%
Future PE
17.05x
Share price in 2028
€121.03

Updated Narratives

MRK logo

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

Fair Value: €143.47 22.9% undervalued intrinsic discount
48 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MRK logo

Legacy Pharmaceutical And Chemical Businesses Will Decline As Regulations Tighten

Fair Value: €105.5 4.8% overvalued intrinsic discount
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MRK logo

Aging Populations And Digitalization Will Unlock Life Sciences Potential

Fair Value: €191 42.1% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with solid track record and pays a dividend.

0 Risks
5 Rewards

Merck KGaA Key Details

€21.3b

Revenue

€8.7b

Cost of Revenue

€12.5b

Gross Profit

€9.6b

Other Expenses

€3.0b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Mar 05, 2026
6.80
58.87%
13.90%
39.5%
View Full Analysis

About MRK

Founded
1668
Employees
62346
CEO
Belen Garijo Lopez
WebsiteView website
www.emdgroup.com

Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography resins, single-use systems, process chemicals, and excipients; and life science services, such as monoclonal antibodies, high-potency active pharmaceutical ingredients, antibody-drug conjugates, and viral and gene therapy products, as well as contract development, manufacturing, and testing services. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, cardiovascular, metabolism, and endocrinology disorders; and provides general medicines, injection devices, and disease monitoring software. The Electronics segment supplies materials comprising thin films, patterning and planarization formulations, specialty gases, optronics, and optical metrology equipment for the semiconductor and display industries, as well as provides delivery systems and services. It has in-licensing agreements with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

Recent MRK News & Updates

Recent updates

No updates